According to the new market research report "Solvent Evaporation Market by Evaporator Type (Rotary Evaporator, Nitrogen Blow Down Evaporator, Centrifugal Evaporator), End-User (Pharmaceutical & Biopharmaceutical, Diagnostic Laboratories, Research & Academic Institute), Region - Global Forecast to 2024", published by MarketsandMarkets™, This study involved the extensive use of both primary and secondary sources.Access Free Sample Research Copy : https://www.marketsandmarkets.com/requestsampleNew.asp?id=68290365
Growth in this market is driven majorly by the growth of the biologics sector, increasing research & development expenditure, rising purity demands in end-use markets, and the growing development of large molecule biopharmaceuticals.The research & academic institutes segment is expected to grow at the highest CAGR during the forecast period. The growth in this segment can be attributed to factors such as the increasing drug development studies and the rising demand for continuous innovation and enhancement of existing products.Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=68290365The rotary evaporators segment is expected to account for the largest solvent evaporators market share in 2018 :Rotary evaporators are expected to be the most significant revenue contributor to the global market in 2018. The large share of this segment can be attributed to the increasing demand for efficient & pure samples, growing investments in research & development by research institutes, rising demand for industrial-scale automation in terms of digitization, and the growing need for advanced analytical tools during drug diagnosis & research studies.What Drives the Market?- Increasing R&D Expenditure- Increasing Demand for Pure Samples in End-Use Markets- Growing Development of Large-Molecule BiopharmaceuticalsGeographical Growth Analysis:The North American market accounted for the largest share of the solvent evaporators industry in 2018. This is attributed to the increase in life sciences R&D, rising focus on improving the safety & quality of healthcare, growing efforts to increase the output of the healthcare industry, growth in the biosimilars & generics market, rising demand for high-quality research tools for data reproducibility, and increasing focus on developing personalized therapeutics. The presence of a large number of global players in this region is another key factor contributing to the large share of this market segment.Get Expert Analysis and Insights of Global Market | Enquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=68290365
According to the new market research report “Particle Therapy Market by Type (Heavy Ion, Proton Therapy), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate, Breast), Application (Treatment, Research) - Forecast to 2023", published by MarketsandMarkets™, The global particle therapy market is projected to reach USD 1,349 million by 2023 from USD 865 million in 2018, at a CAGR of 9.3%.Access Free Sample Research Copy :https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724
This market is segmented into disposable and reusable autoinjectors. The disposable autoinjectors segment is expected to account for the largest market share in 2017. This can primarily be attributed to their ease of use and the presence of a built-in glass syringe which makes it more convenient for patients with reduced dexterity or visual impairments.Autoinjectors are easy-to-handle and cost-effective medical devices that can be used by patients, caregivers, and even untrained personnel to deliver a dose of a particular drug. Autoinjectors are used by patients to manage autoimmune diseases and chronic diseases. They are used for a wide range of indications such as rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis.Download the PDF brochure@https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=12809137Preference for alternative drug delivery modes such as oral diabetic agents, oral insulin, and epinephrine nasal sprays is a major factor restraining the growth of the market. Traditional injectables are invasive and painful modes of drug delivery owing to which patients and care providers are increasingly focusing on alternative routes of drug delivery, such as oral, topical, and nasal routes.Among the various routes of drug delivery, the oral route is the most preferred as it is easy to use, convenient, cost-effective, safe, and acceptable. Moreover, the introduction of needle-free drug delivery devices such as jet injectors also restricts the growth of the autoinjectors market.Growth in the particle therapy market is primarily driven by factors such as the various advantages offered by particle therapy over photon therapy, growing global prevalence of cancer, increasing adoption of particle therapy in clinical trials, and the increasing number of particle therapy centers worldwide.Synchrotrons are used to accelerate both protons and heavy ions such as carbon and hydrogen. The growth of the synchrotrons segment is attributed to factors such as the increasing number of research activities as well as the increasing investments in the development of synchrotron facilities.Request Bundle Reports @ https://www.marketsandmarkets.com/RequestBundleReport.asp?id=12809137Ion Beam Applications SA (Belgium), Varian Medical Systems, Inc. (US), and Hitachi, Ltd. (Japan) are the major players operating in the particle therapy market. Other players in this market include Provision Healthcare (US), Mevion Medical Systems, Inc. (US), Sumitomo Heavy Industries, Ltd. (Japan), Optivus Proton Therapy, Inc. (US), ProTom International, Inc. (US), Advanced Oncotherapy Plc. (UK), and Danfysik A/S (Denmark).By application, treatment applications are expected to be the largest contributor to the particle therapy marketThe introduction of small footprint single-room particle therapy centers is further promoting the adoption of proton therapy for the treatment of cancer in small-scale hospitals. Factors driving the growth of the treatment applications segment include the growing number of cancer patients globally, increasing government initiatives (aimed at equipping or upgrading hospitals with newer and advanced radiotherapy systems), and the increasing availability of funding for the adoption of advanced cancer treatment technologies.
According to a new market research report "Autosamplers Market by Product (Systems (Liquid Chromatography, GC (Liquid, Headspace, All-in-one)), Accessories (Syringe & Needle, Vial, Septum) & Enduser (Pharmaceutical companies, Oil & Gas, Food & Beverage, Environment testing) - Global Forecasts to 2022", published by MarketsandMarkets™, the market is projected to reach USD 1136.2 Million by 2022, at a CAGR of 7.6% from USD 786.1 Million in 2017.The report analyzes and studies the major drivers, restraints, opportunities, and challenges of the Autosamplers Market in North America, Europe, Asia Pacific, and the Rest of the World (RoW). Growing importance of chromatography in drug approvals, increasing production of crude and shale oil, growing food safety concerns, and patent expiry of major drugs and biomolecules are some of the factors driving the growth of the market.Don’t Miss an Opportunity In Autosamplers Market.Request PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=156038985 
Significant Growth Opportunities In Pharma, Biotech, Oil & Gas, Food Industry:Based on end user, the Autosamplers Market is segmented into pharmaceutical and biopharmaceutical industry, oil and gas industry, food and bevarage industry, environmental testing industry, and other end users. Other end user segment including cosmetic industry and academic and government research institutes are expected to be the fastest-growing segment of the market during the forecast period.Based on product, the autosampler systems segment is estimated to be the largest segment of the market in 2017On the basis of product, the Autosamplers Market is segmented into autosampler systems and autosampler accessories. The autosampler systems segment is expected to have the largest share in the Autosamplers Market in 2017 majorly due to increasing adoption of autosamplers in different industries to avoid errors occurred as a result of manual injection systems.The collaborations among major market players and stringent government regulatory frameworks for the cosmetics industry (owing to the hazardous effects of several ingredients used in the manufacturing of cosmetic products) are the major factors driving the segment.North America accounted for the largest share of the Autosamplers MarketGet Sample Pages @http://www.marketsandmarkets.com/requestsample.asp?id=156038985Geographically, the autosmplers market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America accounted for the largest share of the market in 2017, which is driven by the growing importance of chromatography tests in the drug approval process and increasing funds for R&D activities in pharmaceutical and biopharmaceutical industries.The major players of the Autosamplers Market are Agilent (US), Waters (US), Shimadzu (Japan), Thermo Fisher (US), and PerkinElmer (US). The other players in this market include Merck (Germany), Bio-Rad (US), Restek (US), Gilson (US), JASCO (US), and SCION (US).
According to the new market research report " Radiation Dose Management Market by Products & Services (Standalone, Integrated Solutions, Education & Training Services), Modality (Computed Tomography, Nuclear Medicine), and End User (Hospitals, Ambulatory Care Settings) - Global Forecast to 2024", , published by MarketsandMarkets™, The radiation dose management market is projected to reach USD 447 million by 2024 from USD 206 million in 2019, at a CAGR of 16.7% during the forecast period.Access Free Sample Research Copy :https://www.marketsandmarkets.com/requestsampleNew.asp?id=82326344 
The radiation dose management solutions segment is expected to grow at the highest CAGR during the forecast period :Based on product & service, the market is segmented into radiation dose management solutions and radiation dose management services. The radiation dose management solutions segment is projected to witness the highest growth during the forecast period.The computed tomography segment accounted for the largest share of the radiation dose management market in 2018 :By modality, the market is segmented into computed tomography (CT), fluoroscopy and interventional imaging, mammography, and nuclear medicine. The computed tomography segment accounted for the largest market share in 2018.Hospitals accounted for the largest share of the market in 2018:Based on end user, the market is segmented into hospitals, ambulatory care settings, and other end users. The hospitals segment accounted for the largest share of the market in 2018.Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82326344North America accounted for the largest share of the radiation dose management market in 2018 :On the basis of region, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2018, North America accounted for the largest share of the market. The large share of North America can be attributed to factors such as the stringent legislative and accreditation requirements regarding the reporting and optimization of radiation doses, high adoption of HCIT technologies, and the presence of stringent regulatory requirements regarding patient safety.
According to the new market research report " Digital Therapeutic (DTx) Market by Application (Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation), Sales Channel (B2C, Patient, Caregiver, B2B, Providers, Payer, Employer, Pharma) - Global forecasts to 2025, published by MarketsandMarkets™, The global digital therapeutics market is projected to reach USD 6.9 billion by 2025 from USD 2.1 billion in 2020, at a CAGR of 26.7% during the forecast period (2020–2025).Access Free Sample Research Copy : https://www.marketsandmarkets.com/requestsampleNew.asp?id=51646724
The growth of the digital therapeutics market is primarily driven by factors such as government initiatives for preventive healthcare, technological advancements in mobile healthcare, a significant increase in venture capital investments, and the benefits of digital therapeutics, such as the ability to induce behavioral change (an important challenge in healthcare), user-friendliness, patient convenience, and improved drug compliance.On the other hand, a lack of awareness and access to digital therapeutics programs in developing countries, patient data privacy concerns, unstable payment models, and resistance from traditional healthcare providers are challenging the growth of this market to a certain extent.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51646724What Drives the Market?1 Increasing incidence of preventable chronic diseases2 Rising focus on preventive healthcare3 Need to control healthcare costs4 Significant increase in venture capital investmentsGlobal Market Segmentation:Based on the sales channel, the digital therapeutics market is segmented into business-to-customer (B2C) and business-to-business (B2B). In 2019, the B2B segment accounted for the largest market share; it is also expected to grow at the highest CAGR of the digital therapeutics market.Based on the type of buyer, the B2C sales channel market is further segmented into patients and caregivers. The caregivers segment is expected to dominate the market and register the highest CAGR during the forecast period.Based on the application, the digital therapeutics market is segmented into preventive and treatment/care-related applications. One of the key factors driving the growth of this segment is the rise in treatment and healthcare costs, especially due to chronic conditions.Speak to Analyst @ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=51646724Key Players and Strategies Adopted by Them:The digital therapeutics market is fragmented in nature, with a large number of players, including tier 1 and mid-tier companies competing for market shares. The prominent players in the global digital therapeutics market include Noom (US), Livongo Health (US), Omada Health (US), WellDoc (US), Pear Therapeutics (US), Proteus Digital Health (US), Propeller Health (US), Akili Interactive Labs (US), Better Therapeutics (US), Happify (US), Kaia Health (Germany), Mango Health (US), Click Therapeutics (US), Canary Health (US), Wellthy Therapeutics (India), Cognoa (US), Ayogo Health (Canada), Mindstrong Health (US), 2Morrow (US), and Ginger (US).
The global vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016, at a CAGR of 10.5%. The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.On the basis of product type, the market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and other adjuvants.
Access Free Sample Research Copy : https://www.marketsandmarkets.com/requestsampleNew.asp?id=152603894 
Global Vaccine Adjuvants Market Segmentation:The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.+ On the basis of product type, the vaccine adjuvants market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and others. The particulate adjuvants segment is expected to account for the largest share of the global market in 2016. The adjuvant emulsions segment, on the other hand, is projected to grow at the highest CAGR during the forecast period.+ On the basis of route of administration, the market is segmented into oral, subcutaneous, intranasal, intramuscular, intradermal, and others. The intramuscular segment is expected to account for the largest share of the global vaccine adjuvants market in 2016.+ On the basis of disease type, the vaccine adjuvants market is segmented into infectious diseases, cancer, and others. The infectious diseases segment is expected to account for the largest share of the global market in 2016. Factors such as high prevalence of infectious diseases, government & company initiatives, and high prevalence of cancer cases are expected to drive market growth in the coming years.
Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894What Drives the Market?1. Increasing Use of Adjuvants in Vaccine2. High Prevalence of Infectious and Zoonotic Diseases3. Increase in Livestock and Instances of Diseases4. Increasing Focus on Immunization Programs From Various Government Bodies5. Technological Advancements in Aluminum Hydroxide-Based Adjuvants6. Increasing Focus and Support on the Discovery and Development of Vaccine Adjuvants7. Increasing Geriatric PopulationGet Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=152603894Geographical Growth Analysis:Geographically, the vaccine adjuvants market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is projected to grow at the highest CAGR during the forecast period. Growth in the North American segment is primarily driven by the increasing geriatric population and rising incidences of diseases in the North American countries.
The growth of this market is mainly driven by technological advancements, the decreasing prices of DNA sequencing, and the increasing incidence of genetic diseases.According to the new market research report “Genotyping Market by Technology (PCR, Sequencing, Microarray, Electrophoresis, MALDI-TOF), Application (Pharmacogenomics, Diagnostic Research, Animal Genetics, Agricultural Biotechnology), and Product - Global Forecast to 2023", published by MarketsandMarkets™, The genotyping assay market is expected to reach USD 31.9 billion by 2023 from an estimated USD 11.8 billion in 2018, at a CAGR of 22.0%.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249958595 
Key Players and Strategies Adopted by Them:The genotyping market in the APAC is expected to grow at the highest CAGR during the forecast period. This is due to the increasing incidence of chronic diseases, and growing awareness on the use of genotyping tests to control the inheritance of genetic diseases and the spread of infectious and microbial diseases in APAC countries. Global pharmaceutical and biopharmaceutical companies are also increasingly outsourcing clinical research and trials to companies in this region, which has increased the demand for genotyping products for drug profile assessment, drug efficacy and safety assessment, dosing determination, and drug response evaluation.What Drives the Market?Thermo Fisher Scientific (US), Illumina (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US)Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=249958595The reagents & kits segment is expected to grow at the highest CAGR during the forecast periodBased on product, the reagents and kits are expected to grow at the highest rate during the forecast period. This segment is expected to witness the highest CAGR due to the easy accessibility of a wide range of reagents and the increasing need for genotyping in various applications.+ Based on product, the market is divided into reagents & kits, genotyping services, instruments, and bioinformatics. The easy accessibility to a wide range of reagents and need for genotyping in various applications (such as assessing drug efficacy & safety, cutting down cost and time required for clinical development, personalizing the treatments for chronic diseases, and developing good breeds of animals and plants) have contributed to the high and repetitive consumption of reagents and kits as consumables in various genotyping applications.+ Based on technology, the genotyping assay market is segmented into PCR, microarrays, sequencing, capillary electrophoresis, MALDI-TOF, and other technologies. The sequencing segment is expected to account for the largest share of the global genotyping market during the forecast period of 2018 to 2023.Access Free Sample Research Copy : https://www.marketsandmarkets.com/requestsampleNew.asp?id=249958595
According to a new market research report "Compound Management Market by Product & Outsourcing Services (Instruments (Automated Storage, Decapper), Software), Sample (Chemical Compounds, Biological Samples), End User (Biopharma Companies, Biobank, Pharma Companies, CRO) - Global Forecast to 2023", published by MarketsandMarkets™, the global market is projected to reach USD 424.5 million in 2023 from USD 215.3 million in 2018, at CAGR of 14.5%.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=182172928 
The global compound management market is projected to reach USD 424.5 million in 2023 from USD 188.0 million in 2017, at CAGR of 14.5%. The base year considered for the study is 2017, and the forecast for the market size is provided for the period between 2018 and 2023. In the current market scenario, the growth of the market can be attributed to the increasing drug discovery activities, growing biopharmaceutical industry, and rising trend in outsourcing compound/sample management. On the other hand, the large capital investments needed to establish compound management facilities is the major factor restraining market growth.Browse 95 market data Tables and 24 Figures spread through 118 Pages and in-depth TOC on "Compound Management Market"Increasing drug discovery activity :Rising R&D expenditure globally has driven the pace of drug discovery. Most major players in the pharmaceutical industry have committed substantial investments to R&D to fulfill the demand for more effective drugs and therapies, which has proven beneficial to the compound/sample management market.Additionally, the demand for automated compound/sample management is expected to gain momentum in the coming years due to the growing government funding for biotech and drug discovery research worldwide.Request Sample Report :- https://www.marketsandmarkets.com/requestsampleNew.asp?id=182172928North America is expected to account for the largest share of the market in 2018Among the four geographic regions, North America is expected to account for the largest share of the Compound Management Market in 2018, followed by Europe, APAC, and the RoW. The large share of North America is attributed to the presence of the large pharmaceutical and biopharma industry. As a result, several companies in North America are engaged in drug discovery activities, which require maintenance of huge chemical libraries. Moreover, to maintain productivity of such innovative drugs and biologics, most of the leading pharma and biopharma companies have started building compound management facilities.Market PlayersThe Compound Management Market is highly competitive due to the presence of a large number of players. Few companies that provide compound management systems are Brooks Life Sciences (US), Hamilton Company (US), TTP Group (UK), Labcyte (US), Biosero (US), and Tecan (Switzerland).
Rising government investments for cell-based research, the increasing number of GMP-certified production facilities, and the large number of oncology-oriented cell-based therapy clinical trials are the key factors driving the growth of this market. China, India, Japan, Korea, and Brazil are emerging markets for cell therapy instruments.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=889
These markets boast comparatively lenient standards and government regulations as opposed to developed markets in North America and the EU, and thus offer significant growth potential for providers. However, the high cost of cell-based research and the low success rate is expected to restrain market growth to some extent during the forecast period.Cell processing segment to witness the highest growth during the forecast period :Based on process, the cell therapy technologies market is segmented into cell processing; cell preservation, distribution, and handling; and process monitoring and quality control. The cell processing segment is expected to account for the largest market share in 2018 and is projected to witness the highest CAGR during the forecasted period.Browse and in-depth TOC on “Cell Therapy Technologies Market”75 - Tables30 - Figures116 - PagesTo Get Sample Report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=213334978Key players in this market include Beckman Coulter (US), Becton, Dickinson and Company (US), GE Healthcare (US), Lonza (Switzerland), Merck KGaA (Germany), Miltenyi Biotec (Germany), STEMCELL Technologies, Inc. (Canada), Terumo BCT (US), and Thermo Fisher Scientific (US).Thermo Fisher was the largest player in the Cell Therapy Technologies Market in 2017. In order to maintain its position in the market and further expand its product portfolio, the company focuses on the strategies of product launches, acquisitions, and expansions. Merck holds the second position in the cell therapy technologies market. The company focuses on collaborations, agreements, and acquisitions to enhance its market position.North America to dominate the cell therapy technologies market during the forecast period :The market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to dominate the market in 2018 owing to the high burden of chronic diseases and increasing R&D activities in the pharmaceutical and biotechnology industries.Speak to Analyst @ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=213334978
The global non-invasive prenatal testing (NIPT) market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period. Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT. However, a dearth of skilled professionals is restraining the growth of this market.Access Free Sample Research Copy : https://www.marketsandmarkets.com/requestsampleNew.asp?id=145607690
According to the new market research report “Non-Invasive Prenatal Testing Market by Instruments (Ultrasound, NGS, PCR, Microarray), Consumables, Method (FCMB, cf-DNA), Application (Trisomy, Microdeletion, Genetics, Rh factor) & End User (Hospital, Diagnostic Labs) - Global Forecast to 2021", published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia, and the Rest of the World (RoW).Key Players in the Global NIPT MarketThe NIPT market is diversified and highly competitive, with a large number of players competing for market space. The prominent players in the market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), GE Healthcare (US), BGI (China), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer Inc. (US), Laboratory Corporation of America Holdings (US), Natera, Inc. (US), and Yourgene Health (UK)Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145607690Growth prospects in Non Invasive Prenatal Testing (NIPT) Market :The global non-invasive prenatal testing (NIPT) market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period. Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT. However, a dearth of skilled professionals is restraining the growth of this market.By method, the NIPT products market is segmented into ultrasound detection, biochemical screening tests, and cell-free DNA in maternal plasma tests. The cfDNA in maternal plasma tests segment is expected to grow at the highest CAGR during the forecast period.Based on application, the non-invasive prenatal testing (NIPT) market is segmented into trisomy, microdeletion syndrome, and other applications (gender identification and the detection of monogenic disorders, Klinefelter syndrome, and Rhesus (Rh) blood type). In 2018, trisomy was the largest application segment of the NIPT market.Based on end user, the NIPT products market is classified into diagnostic laboratories and hospitals. In 2019, diagnostic laboratories formed the largest and fastest-growing end users of NIPT products.Inquire or share your questions if any before the purchasing this report: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=145607690
According to the new market research report " HLA Typing for Transplant Market by Technology (SSO-PCR, SSP-PCR, NGS, Sanger’s Sequencing), Products & Services (Instruments, Reagents, Software), Application (Diagnostics, Research), End User (Hospitals, Academia, Diagnostic Center) - Forecast to 2021", published by MarketsandMarkets™,The global HLA typing for transplant market is projected to reach USD 753.9 Million by 2021 from USD 535.0 Million in 2016, at a CAGR of 7.1% from 2016 to 2021.
Don’t miss out on business opportunities in HLA Typing for Transplant Market, visit: https://www.marketsandmarkets.com/requestsampleNew.asp?id=96374742Browse and in-depth TOC on " HLA Typing for Transplant Market "60 - Figures203 - PagesGet Free 10% customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=96374742This report studies the global HLA typing for transplant market over the forecast period of 2016 to 2021.Market growth can be attributed to factors such as the rising number of solid organ, soft tissue, and stem cell transplantations; technological advancements in the field of organ transplantation; increased funding, research grants, and public-private investments; technological shift from serological assays to gene-based HLA profiling; and improving healthcare infrastructure across developing countries.To know about the assumptions considered for the study, download the pdf brochure@https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96374742Growth in the sequencing-based molecular assay segment is mainly driven by the growing market demand for high-throughput DNA sequencers in HLA typing, rising end-user preference for low-cost and efficient DNA sequencing technologies, expansion in application horizons of NGS in tissue typing, and increasing usage of NGS systems among researchers and diagnostic laboratories. The PCR-based molecular assay segment is expected to hold a larger share of the global HLA typing for transplant market for molecular assay technology in 2016.
